NANOVIRICIDES, INC. 4
4 · NANOVIRICIDES, INC. · Filed Jan 13, 2015
Insider Transaction Report
Form 4
Diwan Anil
DirectorPresident10% Owner
Transactions
- Purchase
Common Stock
2015-01-12$2.63/sh+3,000$7,890→ 2,064,918 total - Purchase
Common Stock
2015-01-12$2.71/sh+7,392$20,032→ 2,082,310 total - Purchase
Common Stock
2015-01-12$2.62/sh+3,000$7,860→ 2,061,918 total - Purchase
Common Stock
2015-01-13$2.60/sh+5,000$13,000→ 2,069,918 total - Purchase
Common Stock
2015-01-13$2.75/sh+5,000$13,750→ 2,074,918 total
Footnotes (1)
- [F1]Includes 285,714 shares of common stock issuable upon exercise of options held by Dr. Diwan that are currently exercisable. Does not include 16,531,429 shares owned by TheraCour Pharma, Inc. (after calculating the Preferred Series A convertible as converted), over which Dr. Diwan holds voting and dispositive power. Does not include 500,000 shares of the Company's Series A Convertible Preferred Stock (the "Series A") which votes at the rate of nine shares of Common Stock per each share of Series A and is convertible into three and one half shares of Common Stock upon a change in control of the Company or upon achieving certain trading prices of the Common Stock (the "Series A Preferred Stock").